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Abstract
As indicators of responsiveness to a tumour necrosis factor
(TNF)α blocking agent (infliximab) are lacking in rheumatoid
arthritis, we have used gene profiling in peripheral blood
mononuclear cells to predict a good versus poor response to
infliximab. Thirty three patients with very active disease (Disease
Activity Score 28 >5.1) that resisted weekly methotrexate
therapy were given infliximab at baseline, weeks 2 and 6, and
every 8th week thereafter. The patients were categorized as
responders if a change of Disease Activity Score 28 = 1.2 was
obtained at 3 months. Mononuclear cell RNAs were collected at
baseline and at three months from responders and non-
responders. The baseline RNAs were hybridised to a microarray
of 10,000 non-redundant human cDNAs. In 6 responders and 7
non-responders, 41 mRNAs identified by microarray analysis
were expressed as a function of the response to treatment and
an unsupervised hierarchical clustering perfectly separated
these responders from non-responders. The informativeness of
20 of these 41 transcripts, as measured by qRT-PCR, was re-
assessed in 20 other patients. The combined levels of these 20
transcripts properly classified 16 out of 20 patients in a leave-
one-out procedure, with a sensitivity of 90% and a specificity of
70%, whereas a set of only 8 transcripts properly classified 18/
20 patients. Trends for changes in various transcript levels at
three months tightly correlated with treatment responsiveness
and a down-regulation of specific transcript levels was observed
in non-responders only. Our gene profiling obtained by a non-
invasive procedure should now be used to predict the likely
responders to an infliximab/methotrexate combination.
Introduction
Rheumatoid arthritis (RA) is a chronic, auto-immune and
inflammatory polyarthritis that induces joint damage and disa-
bility. Tumour necrosis factor (TNF)α plays a key role in the
associated pathological events and has been identified as a
therapeutic target. In fact, TNFα blocking agents (TBAs), such
as infliximab, etanercept, and adalimumab, have revolutionized
the therapeutic care of methotrexate-resistent patients. Vari-
ous clinical trials with a TBA/methotrexate combination have
shown efficacy in 60% to 80% of such patients [1-3].
TBAs reduce joint inflammation, slow down joint damage and
improve physical function [4,5]. Still, 20% to 40% of the RA
patients given a TBA/methotrexate combination do not
respond to this treatment [1-3]. Moreover, TBAs may have
side effects and are costly [6] and the efficacy of any given
TBA in a given patient is unpredictable [7,8]. For these rea-
sons, predicting responsiveness to a given TBA or other
emerging biotherapies (such as inhibitors of the interleukin-1
or interleukin-6 pathways) would be most useful. Markers that
have proven informative for RA diagnosis or prognosis, such
CRP = C-reactive protein; DAS = disease activity score; DMARD = disease-modifying anti-rheumatic drug; PBMC = peripheral blood mononuclear 
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as C-reactive protein (CRP), erythrocyte sedimentation rate,
autoantibodies (for example, rheumatoid factors and anti-
cyclic citrullinated peptide antibodies), metalloproteinases
and bone proteins cannot predict the responsiveness to TBAs
[9].
Because genetic polymorphisms such as HLA-DR haplotypes
have been associated with a variable natural course of RA and
a heterogeneous response to conventional disease-modifying
anti-rheumatic drugs (DMARDs), a few studies have
attempted to identify genetic markers for TBA efficacy and
they have focused on the promoters of several cytokine genes
[10-12]. For example, sequence variation in the TNFα gene
promoter has been associated with a variable response to inf-
liximab [11]. However, similar conclusions hold true for etaner-
cept as well [13] and, therefore, such genotypings are useless
for selecting the TBA with greatest benefits [14].
Because response to treatment likely depends on polymor-
phisms at multiple loci [15], genome-wide analysis of gene
expression with cDNA arrays has been recently used to iden-
tify markers of responsiveness in the peripheral blood mono-
nuclear cells (PBMCs). However, the number of such studies
is still very limited [16,17] and very few informative genes have
been identified [16]. Moreover, in all instances, too few
patients per study precluded statistically valid conclusions
[17] or a confirmatory analysis in another, independent set of
patients [16].
Owing to transcriptome analysis in PBMCs from RA patients,
we have now identified a small subset of transcripts whose
combined levels allow one to reliably predict the response to
a infliximab/methotrexate combination in methotrexate-resist-
ant patients with very active disease.
Materials and methods
Patients
A total of 33 patients, fulfilling the American College of Rheu-
matology (ACR) criteria for RA [18] and followed in Rouen
University Hospital were included in this study. The criteria for
patient eligibility were: methotrexate treatment; disease activ-
ity score 28 (DAS28) = 5.1 [19]; and resistance to at least
one DMARD (methotrexate included). Exclusion criteria were:
evolving infectious disease; age <18 years; no contraception;
Table 1
Primers used for qualitative RT-PCR
Transcript Forward Reverse
AKAP9 5'-TGTTACTGGGTGGGTTCCAG-3' 5'-CAGAACCTGTGACTCGATGC-3'
COX7AL2 5'-TGATTTCCCTGGAGGTTCTG-3' 5'-CCCCGAGGTGACTAACTCAA-3'
ELMOD2 5'-AGCTCCTGCTCCCCCTAGTT-3' 5'-TCGCTGCAATTCACACTTCC-3'
EPS15 5'- GTCTTCCTTCCCCTCCCTTG-3' 5'-GCAGCATCAGAAGCCAACAC-3'
FBOX5 5'-CGCTGTAATTCACCTGCAAA -3' 5'-GTACCAGGCAGGGGACCTAT-3'
HLA-DPB1 5'-GACCTTCCAGATCCTGGTGA-3' 5'-CTTTCTTGCTCCTCCTGTGC-3'
LAMR1 5'- GCAGCAGGAACCCACTTAGG-3' 5'-AATGGCAACAATTGCACGAG-3'
MCP 5'-AGCAATTTGGAGCGGTAAGC-3' 5'-GTCCAGGTGCAGGATCACAA-3'
MRLP22 5'-CTCCACAACTGCCTGGAGAA-3' 5'-AACTGAGCCAAAGCCTGGTC-3'
MTCBP1 5'-GGAGAAGGGAGACATGGTGA-3' 5'-ACGAGGCACGTGTTAGTTCC-3'
PFKFB4 5'-TGGATCCCAAGTCCTTTGTG-3' 5'-CGCCTTGGACATCTCTTAGC-3'
PSMB9 5'-GGTTCTTGATTCCCGAGTGTC-3' 5'-CAGCCAAAACAAGTGGAGGT-3'
PTPN12 5'-TCCAGCGGGAGGTATTCACT-3' 5'-TGGTCCTTTGGGTTTTCCAC-3'
QIL1 5'-CCTCATCAAGGGAAGTGTGG-3' 5'-GGAGTCACGGATGGGAAAGT-3'
RASGRP3 5'-CAGCAAAGGGCAGAAGTCAT-3' 5'-TAATTGCCGTTGGAGGAGAC-3'
RPL35 5'-ACCTGAAGGTGGAGCTGTCC-3' 5'-AGAACACGGGCAATGGATTT-3'
RPS16 5'-AGTTCTGCTTCTCGGCAGG-3' 5'-TCTTGGAAGCCTCATCCACA-3'
RPS28 5'-GACCGGTTCTCAGGGACAGT-3' 5'-TGACTCCAAAAGGGTGAGCA-3'
SCAM1 5'-TGTGGCCCAGTACACCTTCA-3' 5'-CACGTAGCTGGCAGGGAATA-3'
TBL2 5'-GATGGGGGCTACACCTTCAC-3' 5'-TGACCCTTCAGGCTCCAGAT-3'
18S 5'-GTGGAGCGATTTGTCTGGTT-3' 5'-CGCTGAGCCAGTCAGTGTAG-3'Available online http://arthritis-research.com/content/8/4/R105
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pregnancy; cancer less than 5 years old; cardiac failure (stage
III-IV of the New York Heart Association); and infliximab allergy.
This protocol (numbered 2003/007) was approved by the eth-
ics committee of Haute-Normandie (France) and all partici-
pants signed an informed consent at the time of enrolment. For
one month or more before the start of this study every patient
was given fixed amounts of a DMARD and nonsteroidal anti-
inflammatory drug (NSAID) and did not receive any intra-artic-
ular steroid injections. During this study, every patient was
given the same doses of methotrexate and prednisone as used
before, and was treated with infliximab (Remicade®, Schering-
Plough, Levallois Perret, France) as recommended by the
manufacturer and the French Drug Agency AFSSAPS (intra-
venous 3 mg/kg infliximab at weeks 0, 2, 6, and every 8th week
thereafter). Before each infiximab infusion, DAS28, plasma
CRP level, patient's assessment of pain (0 to 100 mm visual
analogue scale), duration of morning stiffness, and physical
function scored with the French version of the Health Assess-
ment Questionnaire for RA [20] were recorded. Just before
the 4th infusion (that is, at 3 months), the patients were cate-
gorized as responders whenever a change of DAS28 = 1.2
was obtained. All others were categorized as non-responders.
PBMC isolation and mRNA extraction and labelling
The PBMCs were isolated from venous blood by Ficoll-
Hypaque centrifugation and total RNAs were extracted by a
standard phenol/chloroform procedure, quality controlled on
an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto,
Table 2
Demographic and clinical data of rheumatoid arthritis patients at entry of study
Parameter Respondersa Non-responders
Subset 1b (n = 6) Subset 2 (n = 10) Subset 1 (n = 7) Subset 2 (n = 10)
Age (years) 54.1 ± 13.8c 55.2 ± 9.2 56.1 ± 11.7 58.9 ± 11.6
Sex (men/women) 1/5 2/8 1/6 4/6
RA duration (years) 11.7 ± 8.0 11.1 ± 7.3 12 ± 10.2 10.5 ± 5.3
Methotrexate (mg/week)d 12.5 ± 5.5 13 ± 2.8 15.4 ± 2.7e 11.5 ± 3.2
Prednisone (mg/day) 12.1 ± 5.6 8.5 ± 4.2 10.3 ± 8.7 8.2 ± 5.4
Patients with NSAIDs 3 6 5 4
Patients with rheumatoid factor 4 8 5 6
Patients with anti-CCP absg 3858
aCategorised as indicated in Materials and methods. bTranscript levels were measured by microarray analysis for subset 1 or qRT-PCR for subset 
2. cMean ± standard deviation. dMaximally tolerated dose in a given patient. eSignificant difference between subsets 1 and 2 within non-
responders (p < 0.05, Mann and Whitney's non-parametric test). In this table, all other comparisons were non-significant. Anti-CCP abs, anti-
cyclic citrullinated peptide antibodies; NSAID, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis.
Table 3
Clinical data at baseline and at 3 months
Responders Non-responders
S u b s e t  1S u b s e t  2S u b s e t  1S u b s e t  2
Baseline 3 monthsa Baseline 3 monthsa Baseline 3 monthsa Baseline 3 monthsa
Morning stiffness 
(minutes)b
245 ± 126c 35 ± 24.5c 210 ± 81 58 ± 70.2c 179 ± 159 66.4 ± 86c 133 ± 84 62 ± 67.6c
DAS28 b 6.4 ± 1.0 4.2 ± 0.9c 6.2 ± 0.7 3.8 ± 0.6c 5.7 ± 0.8 5.3 ± 1.0 5.5 ± 1.0 4.9 ± 1.0c
Pain (0–100 mm VAS) 59.3 ± 20.3 29.3 ± 9.3c 62.5 ± 15.5 31.3 ± 14.5c 69.3 ± 13.1 54.1 ± 22.1 60.9 ± 11.4 40.6 ± 18.4c
ESR (mm/hour) 44 ± 26.2 27 ± 20.3c 27.2 ± 15.7 11.3 ± 5.2c 35.7 ± 25.7 28.3 ± 15.3 24.1 ± 11.5 27.8 ± 19.2
CRP (mg/l)b 42 ± 29.8 20 ± 15.7c 28.6 ± 19.7 6.2 ± 6.1c 18.5 ± 12.7 13 ± 8.2 15.8 ± 15.6 11 ± 7.3
HAQ score (0–3 scale) 1.6 ± 0.4 0.9 ± 0.5c 1.8 ± 0.7 1.2 ± 0.7c 1.6 ± 0.4 1.2 ± 0.3 1.5 ± 0.4 1.5 ± 0.4
Values are mean ± standard deviation. aResponse assessed just before the fourth infliximab/methotrexate infusion. Significant differences 
between groups are as follows: bdifference between all responders versus non-responders at baseline (0.03 <p < 0.05, Mann and Whitney's 
test); other comparisons were non-significant (p = 0.58); cDifference at baseline versus 3 months in this subset (p < 0.05, paired Wilcoxon's test). 
CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; VAS, visual 
analogue scale (patient's assessment of pain).Arthritis Research & Therapy    Vol 8 No 4    Lequerré et al.
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USA) and frozen at -80°C until further use. An internal, arbi-
trary standard was made of a mixture of total RNAs from
PBMCs taken from three healthy donors. The oligodT-primed
poly(A) mRNAs were labelled with [α33P]dCTP as previously
described [21], and the resulting, labelled cDNAs were imme-
diately used for hybridisation.
Transcriptome analysis and qRT-PCR
Our array covering 12,000 cDNA probes for 10,000 non-
redundant genes and various negative controls as well as
nylon arraying of PCR-amplified probes and hybridisation of
[α33P]dCTP-labelled mRNAs have all been extensively
described and validated in a previous report [21]. Briefly,
cDNA probes selected on the basis of a tissue-preferred
expression in liver corresponded to genes with a liver-
restricted expression (10% of the probes) as well as genes
with an hepatic expression along with a broad expression in
some (50%) or many non-hepatic tissues (40%) [21]. All
arrays were made from a single batch of cDNA probes. Every
RNA sample was hybridised at least twice on separate arrays.
Whenever necessary, the sequence of cDNA probes was con-
trolled with an ABI3100 capillary sequencer (Applied Biosys-
tems APPLERA-France, Courtaboeuf, France). Real-time,
quantitative reverse transcription PCR (qRT-PCR) of mRNAs
and normalization with the 18S RNA amount were done in
duplicate as described [21]. The primers designed with the
Primer3 software [22] are listed in Table 1.
Image analysis and data mining
Image analysis with the XDotsReader software, version 1.8
(COSE, Le Bourget, France), subtractions of noise and spot
background, and image normalization with the median value of
all signals per image were done exactly as previously detailed
[21]. A transcript was considered to be expressed if at least
two hybridisations provided a positive signal. The resulting,
normalized values were used for a selection of significantly
Figure 1
Clustering of rheumatoid arthritis patients as responders versus non-responders Clustering of rheumatoid arthritis patients as responders versus non-responders. Transcripts in peripheral blood mononuclear cells from six respond-
ers (R) or seven non-responders (NR) who were included in two training subsets (subset 1 in text and Tables 2 and 3) were studied by microarray 
analysis. Informative transcripts as selected by a statistical analysis (t test, 25 transcripts; significance analysis of microarrays (SAM), 37 transcripts) 
were next used for an unsupervised hierarchical clustering of the same 13 patients, listed as columns. The gene names are listed as rows (expressed 
sequence tags are noted with a plain, five to six digit IMAGE clone number). The genes are underlined whenever they were selected by both SAM 
and t test. Transcript levels are expressed as ratios (level in sample/level in internal, arbitrary standard). Scale bar (log2 ratio): decreased (green), 
increased (red) or identical (black) ratio in sample versus standard (grey squares are missing values).Available online http://arthritis-research.com/content/8/4/R105
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Table 4
Transcripts as predictors of infliximab responsiveness
IMAGE clonea Encoded protein Symbolb Gene localisation SAMc t testd
295669 Clone 10PTELO13 - - -3.77 0.001
77684 CytP450, family 3, subfamily A, polypeptide 4 CYP3A4 7q21.1 -2.90 <10-4
417137 A kinase (PRKA) anchor protein 9 AKAP9 7q21-q22 -2.83 0.002
415079 Hypothetical protein DKFZp566M1046 - - -2.78 0.001
1848509 RP1 containing part of thyroid hormone receptor-
associated protein 3
THRAP3 1p34.3 -2.56 NS
234261 RP11-750K11 - - -2.53 NS
198699 C-X-C chemokine ligand 5 (ENA78) CXCL5 4q12-q13 -2.50 NS
730048 Ribosomal protein SA (37LRP) LAMR1 3p21.3 -2.43 0.007
56923 F-box protein 5 FBXO5 6q25-q26 -2.42 0.006
1524020 RAS guanyl releasing protein 3 (calcium and 
DAG-regulated)
RASGRP3 2p25.1-p24.1 -2.41 0.004
756784 WD repeat domain 39 WDR39 2q11.2 -2.40 NS
244313 Bac clone RP11-576F1 - - -2.39 0.002
124452 6-Phosphofructo-2-kinase/fructose-2,6-
biphosphatase 4
PFKFB4 3p22-p21 -2.33 0.003
724887 Major HLA, class II, DP beta 1 HLA-DPB1 6p21.3 -2.32 <10-4
416493 Ribosomal protein L35 RPL35 9q34.1 -2.25 NS
191599 Hypothetical protein FLJ13614 - - -2.23 0.006
726045 Ribosomal protein S16 RPS16 19q13.1 -2.24 NS
772993 Similar to 40S ribosomal protein S28 RPS28 19p13.2 -2.23 NS
110169 Proteasome subunit β type 9 (LMP2) PSMB9 6p21.3 -2.17 0.006
346678 Musculoskeletal, embryonic nucleic protein 1 MUSTN1 3p21.1 -2.16 NS
741027 Vinexin β (SH3-containing adaptor molecule-1) SCAM-1 8p21.3 -2.15 NS
428222 EGF receptor pathway substrate 15 EPS15 1p32 -2.12 0.003
740374 Transducin (beta)-like 2 TBL2 7q11.23 -2.12 Ns
774502 Protein tyrosine phosphatase, non-receptor type 
12
PTPN12 7q11.23 -2.09 NS
320298 Membrane-type 1 matrix metalloprotein 
cytoplasmic tail binding protein 1
MTCBP-1 2p25.2 -2.04 0.005
148134 RP1-29K1 containing KiAA0426 -- N S 0 . 0 0 2
127203 CytP450, family 4, subfamily F, polypeptide 12 CYP4F12 19p13.1 NS 0.005
428560 QIL1 protein QIL1 19p13.3 NS 0.009
810626 Cytochrome c oxidase subunit VIIa polypeptide 2 
like
COX7A2L 2p21 NS 0.007
123983 Clone PR13 - - +1.80 NS
486624 ELMO domain containing 2 ELMOD2 4q31.21 +1.85 NS
114519 FLJ 14775 - - +1.90 0.007
357960 Mitochondrial ribosomal protein L22 MRPL22 5q33.1-q33.3 +1.99 0.009
82303 Hypothetical protein BC009264 - - +2.12 NS
247517 Mucin and cadherin-like MUCDHL 11p15.5 +2.40 NS
194455 Membrane cofactor protein (CD46) MCP 1q32 +2.30 0.005
247176 RP116103J18 - - +2.41 <10-4
195723 Kininogen 1 KNG1 -3q27 +2.46 0.009Arthritis Research & Therapy    Vol 8 No 4    Lequerré et al.
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regulated mRNAs, that is, those with an abundance that dif-
fered in two or more comparisons between two samples,
using a funnel-shaped confidence interval (p < 0.05) calcu-
lated from every mRNA detected per hybridisation [21]. This
results in a false discovery rate that is below 10% of the total
number of regulated mRNAs. Statistical analyses were done
with the R software [23]. The TIGR Multiexperiment viewer
(Tmev version 2.2) [24] was used for unsupervised hierarchi-
cal clustering (HC) using the average dot product and com-
plete linkage options, the leave-one-out cross-validation, and
the supervised statistical tool Significance Analysis of Micro-
arrays (SAM) for identification of discriminant transcripts [25]
with a false discovery rate set at <1%. Information about our
clinical and experimental data complies with the recommenda-
tions for the minimum information about microarray experi-
ments (MIAME) and the raw data have been deposited
(accession number GSE3592) in the GEO repository [26].
Results
RA patients and response to treatment
We categorized patients into two groups, responders (R1 to
R16) and non-responders (NR1 to NR17) to an infliximab/
methotrexate combination, at three months according to the
EULAR criteria, as recommended [18]. Tables 2 and 3 provide
demographic and clinical information for these 33 patients, at
entry and at 3 months. The average disease duration was 11
to 12 years and the DAS28 score indicated that all these
patients had a high level of RA activity, which fits with their
resistance to one or more DMARDs. Before treatment, three
variables (morning stiffness, DAS28, CRP level) were slightly
different in responders compared to non-responders. Follow-
ing treatment, the DAS28 score significantly improved at 3
months in responders (average decrease 2.3) whereas it
remained high in non-responders (average decrease 0.4).
Patients in both groups were randomly separated into either a
training subset (subset 1) for transcriptome analysis or a vali-
dation subset (subset 2) for qRT-PCR. At this stage, we paid
attention to retaining a relatively large number of patients in
subset 2 of both groups. As noted in Tables 2 and 3, most fea-
tures did not significantly differ between the paired subsets 1
and 2.
Gene profiling in pre-treatment PBMCs correlates with 
treatment responsiveness
Gene profiling in PBMCs was studied in the two training sub-
sets (subset 1) of the responders and non-responders groups
(a total of 13 patients). On average, 5,282 ± 1,253 transcripts
were detected in PBMCs, with 86% overlap in transcript iden-
tities between responders and non-responders (data not
shown). To precisely identify the transcripts that were differen-
tially regulated in responders compared to non-responders,
we first selected every transcript whose level in at least one
responder was significantly different from the median value in
non-responders or vice versa. This was assessed with a fun-
nel-shaped confidence interval (see Materials and methods; p
< 0.05) and resulted in 2,239 transcripts with an abnormal
level in at least 1 out of these 13 patients. From these 2,239
transcripts, we next selected every transcript whose variation
between responders and non-responders was statistically sig-
nificant according to a t test (25 transcripts) and/or SAM (37
transcripts); these transcripts are listed in Figure 1 (total, 41
transcripts; overlap between t test and SAM selections, 21
transcripts) and detailed in Table 4. The identity of the corre-
sponding microarray cDNA probes was verified by sequenc-
ing. Finally, we performed an unsupervised hierarchical
clustering of the 13 patients above (subset 1). This was based
on the levels of the 25 or 37 transcripts indicated above that,
in both instances, resulted in a perfect separation of the
responders and non-responders into two major clusters (Fig-
ure 1).
We wished to confirm that a combination of the above tran-
script levels could be used as a predictor of responsiveness.
For this purpose, we aimed to measure the levels of the above
41 transcripts by qRT-PCR and compare them between our
two validation subsets (subset 2) from the responder and non-
responder groups (a total of 20 patients). However, among
these 41 transcripts, 12 putative transcripts were identified by
only one IMAGE clone without knowledge of the intron/exon
structure and, therefore, they were not retained. Moreover,
among the 29 remaining transcripts, 9 of them failed to pro-
vide reliable data by qRT-PCR, despite repeated attempts with
various primers. Eventually, 20 out of our 41 transcripts could
be reliably quantified by qRT-PCR. As shown in Figure 2a, an
unsupervised hierarchical clustering of the 20 patients in sub-
set 2 from the two groups, as based upon these 20 transcript
levels, resulted in two major clusters of responders versus
239932 ELAC homolog 2 - - +2.46 NS
244896 Aminoadipate aminotransferase AADAT 4q33 +2.52 0.002
193472 RP11-722P15 - - +2.68 0.002
aIMAGE clone number as a unique identifier. bBold indicates a transcript that was further tested by qRT-PCR. cSignificance analysis of microarrays 
(SAM) value as an indicator of significant transcript variation in responders versus non-responders. A positive or negative value indicates an over- or 
underexpression at baseline in responders versus non-responders, respectively. dP value of a t test as an indicator of significant transcript variation 
in responders versus non-responders. NS, non- significant.
Table 4 (Continued)
Transcripts as predictors of infliximab responsivenessAvailable online http://arthritis-research.com/content/8/4/R105
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non-responders, with 5 misclassified patients (NR8, NR12,
NR17, R13, R16). Despite being informative, such a hierarchi-
cal clustering lacks statistical power, and the efficiency of the
above set of 20 transcripts for patient classification was thus
further evaluated by leave-one-out cross-validation [24]. This
procedure identified 4 misclassified patients and indicated
that this set of transcripts provides 90% sensitivity and 70%
specificity for identification of responders and non-responders
(Table 5).
To determine the minimal number of transcripts that should be
measured for an acceptable prediction of responsiveness, we
tested a series of combinations of transcripts in the 20
patients from each subset 2, and we varied the number and
identity of the transcripts actually used (data not shown). With
a given set of only 8 transcripts, 16 out of 20 patients could
be correctly classified as responders or non-responders by
hierarchical clustering (Figure 2b). Finally, leave-one-out
cross-validation (Table 5) identified only two misclassified
patients and indicated that a given set of 8 transcripts as a pre-
dictor of responsiveness was at least as accurate as the set of
20 transcripts above.
Post-treatment transcript levels correlate with treatment 
responsiveness
We investigated whether the differences in transcript levels
seen in responders compared to non-responders at baseline
were also retained at three months. The data obtained by qRT-
PCR with PBMCs are presented in Figure 3. In responders, 18
out of 20 transcripts (90%) exhibited a trend towards an
increased level at 3 months, although the differences with
respect to the levels at baseline were not significant. Strikingly,
in non-responders, 19 out of 20 transcripts (95%) exhibited an
opposite trend, that is, a decreased level at 3 months, and this
difference was statistically significant for each of 8 transcripts
(Figure 3). Overall, the differences in numbers of up- versus
down-regulated transcripts in responders versus non-
responders were highly significant, whether considering only
the number of transcripts with a significant difference at base-
line versus 3 months (n = 8, p = 3.10-3, Fisher's exact test) or
considering the complete set of transcripts and associated
trends (n = 20, p < 10-4 by Fisher's exact test, or p = 0.007 by
analysis of variance). This argues for a regulation of the corre-
sponding genes by one (or more) TNFα-dependent
pathway(s).
Discussion
The small set of biological markers usually used for RA diag-
nosis or prognosis is unable to predict individual responsive-
ness to TBA [14]. Therefore, to enable such a prediction,
global approaches based on proteomics or transcriptomics
have been recently considered [27,28]. However, in the con-
text of RA, proteomic analysis is still under development [27].
Moreover, very few informative transcripts have been identified
by gene profiling [16] and the few studies that used this
approach have relied on the differences in transcript levels
measured at baseline versus two to three days after treatment
onset [17]. This required exposure of every patient to treat-
ment. Furthermore, the narrow time frame of this procedure
may blur some significant but late variations with respect to
baseline, which eventually limits transcript informativeness. In
contrast, we have now measured transcript levels at baseline
Figure 2
Validation of a narrow selection of transcripts as a tool for clustering responders versus non-responders Validation of a narrow selection of transcripts as a tool for clustering responders versus non-responders. Ten responders (R) and ten non-respond-
ers (NR) were included in two validation subsets (subset 2 in text and Tables 2 and 3). In any given sample of peripheral blood mononuclear cells, 
the abundances of informative transcripts were determined by qRT-PCR and normalized with the corresponding 18S RNA level. Unsupervised hier-
archical clusterings obtained with (a) 20 or (b) 8 selected transcripts are shown. Expression of transcript levels and scale bar are as in Figure 1.Arthritis Research & Therapy    Vol 8 No 4    Lequerré et al.
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as the single predictor of responsiveness. In clinical practice,
prediction can then be done without any exposure to treat-
ment, which enables it to be restricted to responders.
Three months of treatment was chosen as the endpoint of our
study, as recently recommended by international experts [29],
because the objective of an efficient RA treatment is a rapid
response. Should this early evaluation at three months dis-
close a moderate or absent response, this procedure allows
another treatment to be used as early as possible. Also, using
the DAS28 evolution at three months for classifying our 33
patients as responders or non-responders turned out to be
quite reliable in the long run. Indeed, 22 out of 33 patients
could be followed for three more years and their infliximab
responsiveness, or lack thereof, did not vary over this period,
even when increasing infliximab amount and frequency in non-
responders (data not shown).
We aimed to identify a list of transcripts whose combined lev-
els could be related to infliximab/methotrexate responsive-
ness. In fact, infliximab used alone is known to be efficient only
for a short durationbecause the rapid production of anti-inflixi-
mab antibodies counteracts the drug's effect, whereas meth-
otrexate advantageously limits this occurrence. The mixture of
a cytokine inhibitor (infliximab) and an inhibitor of cell prolifer-
ation (methotrexate) is likely to regulate or even co-regulate a
complex set of genes; this is a limitation if an understanding of
some underlying events in RA is desired.
Gene expression was measured in PBMCs because this is an
acknowledged, non-invasive procedure for diagnosis or prog-
nosis of autoimmune diseases [30]. Specifically, in the context
of RA, PBMCs as a surrogate tissue are advantageous as they
allow for screening in any subject, whereas synovium is ame-
nable to analysis in only a few patients. However, a drawback
of such PBMC analysis is the lack of a clear-cut relationship
between PBMCs and the affected synovium, which prevents
the resulting data from providing an understanding of the RA-
associated events in joints. Also, we analysed the PBMC tran-
scriptome with an arbitrary collection of approximately 10,000
cDNA probes [21]. Since this restrictive procedure cannot
measure every transcript expressed in the PBMCs, it does not
intend to provide a genome-wide view of the RA-associated
gene dysregulations in this tissue. Yet, this approach is quite
acceptable when inferring prognosis from gene profiling is the
major task.
Overall, the present study was not designed primarily to
increase our understanding of RA physiopathology but is
mostly suited to the predictive use of some combined tran-
script levels. Our data illustrate that a non-invasive transcrip-
tome analysis done in PBMCs with an array of probes devoid
of a specific selection towards the disease under study ena-
bles the efficient prediction of treatment responsiveness.
Whether these conclusions are solid whatever the microarray/
Figure 3
Relative transcript levels at baseline versus three months in responders  or non-responders Relative transcript levels at baseline versus three months in responders 
or non-responders. The patients and transcripts are as in Figure 2a. For 
every transcript, the 4 levels (median value) shown at baseline and after 
3 months in responders and non-responders are expressed as a per-
centage of the median level at baseline in responders (100%). Signifi-
cant differences are all noted in the non-responder panel: asterisk 
outside closed bar, difference in non-responders at baseline versus 
three months (p < 0.05, paired Wilcoxon's test); asterisk within open 
bar, difference at baseline in responders versus non-responders (p < 
0.05, Mann and Whitney's test); asterisk within closed bar, difference 
at 3 months in responders versus non-responders (p < 0.05, Mann and 
Whitney's test). In any patient group, a trend towards an increased or 
decreased level was considered whenever the value at 3 months was, 
respectively, above or below the value at baseline, whatever the differ-
ence of these values. Note that standard deviations are not shown 
because they are useless for non-parametric statistical tests.Available online http://arthritis-research.com/content/8/4/R105
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qRT-PCR platforms used, depend on a restricted PBMC sub-
population, or, above all, are useful in the context of an actual
therapeutic decision, remains to be tested.
By t test and/or SAM, we identified a short list of 25 to 37 tran-
scripts whose combined expression levels in PBMCs are an
efficient discriminator of responders versus non-responders to
infliximab/methotrexate. Many of the 25 transcripts identified
by t test were no longer significant when using Bonferroni's
correction to adjust statistics for the multiple transcripts ana-
lysed, but Bonferroni's correction has been recognized as a
drastic one when used in this context, which contrasts with the
SAM-associated false discovery rate [31]. Moreover, the t test
and SAM cross-validated each other for most of the 20 tran-
scripts eventually selected for qRT-PCR as 13 out of 20
(65%) such transcripts were significant with both tests (Table
4). Measuring these 20 transcript levels by qRT-PCR indi-
cated that their performance as a predictor of responsiveness
was equal to that obtained with 37 transcripts. Ultimately, a
given combination of 8 selected transcripts (75% of them
being significant by t test and SAM) as a predictor of respon-
siveness was as powerful as any higher number of transcripts.
This observation that a given combination of very few tran-
scripts can equal or even outperform the predictive strength of
a higher number of transcripts has also been reported in
another context, namely the response to hepatitis C treatment
[32]. This small size for an informative gene set is most encour-
aging when the need comes for the development of a reliable,
fast and cheap assay for measuring informative transcript lev-
els in a clinical setting.
Consistent with the limitations noted above, our list of 29 tran-
scripts did not disclose any significant series of transcripts
whose altered levels could point to the physiopathological
importance of a predominating function or pathway. Indeed,
these transcripts covered such diverse proteins and functions
as: ribosomal components (LAMR1, MRPL22, RPL35,
RPS16, RPS28), which may suggest the existence of a TNFα-
dependent pathway in the control of translation; cell adhesion
and inhibition of cell migration/invasion (LAMR1, MUCDHL,
MTCPB1); cytochromes (CYP3A4, CYP4F12) and cyto-
chrome oxidase (COX7A2L); proteasome-mediated proteoly-
sis (FBXO5, PSMB9); various enzymes (AADAT, PFKFB4);
intra- or extracellular signalling (AKAP9, CXCL5, PTPN12,
RASGRP3, TBL2, THRAP3), including regulators of the ERK
pathway (EPS15, SCAM-1); and innate or adaptive immunity
(KNG1, MCP, PSMB9, HLA-DPB1). Two transcripts, namely
MUSTN1 and HLA-DPB1, are noteworthy; the MUSTN1 tran-
script codes for a protein involved in bone development and
regeneration [33] and some alleles of the HLA-DPB1 gene
have been associated with a relatively high risk of RA occur-
rence [34].
The opposite variations in transcript levels seen in responders
compared to non-responders at three months strongly sug-
gest that the informative transcripts retained in our study orig-
inated from TNFα-regulated genes. In fact, TNFα-dependent
expression of the CXCL5,  CYP3A4,  LAMR1,  MCP, and
PSMB9 genes, as noted here, has been previously described
[35-40]. However, only two of our transcripts, namely MCP
and PTPN12, are found among lists of genes that are directly
regulated by the TNFα/NFκB pathway, whether in RA [41] or
in another context [42,43]. Therefore, it is likely that most of
our transcripts are indirect TNFα targets. This view fits with the
fact that the opposite variations in responders versus non-
responders were observed weeks after the start of TBA. The
reason why the transcript levels exhibited a limited trend to up-
regulation at three months in responders along with a predom-
inating repression in non-responders (Figure 3) also fits with
indirect TNFα target genes, whose regulation would depend
Table 5
Performance of the number of transcripts for prediction of responsiveness
Number of selected transcriptsa
20 8
Number of NR patients classified as NRb 71 0
Number of NR patients classified as Rb 30
Number of R patients classified as Rb 98
Number of R patients classified as NRb 12
Fisher's exact testc p < 0.02 p < 0.0007
Sensitivity 90% 80%
Specificity 70% 100%
Positive predictive value 75% 100%
Negative predictive value 87.5% 83%
aAs listed in Figure 2a, b. bBy leave-one-out cross-validation with 20 patients, including 10 non-responders (NR) and 10 responders (R) (referred 
to as validation subset 2 in the text). cP < 0.05 indicates a significant link between transcript-based classification (R versus NR) and actual 
responsiveness.Arthritis Research & Therapy    Vol 8 No 4    Lequerré et al.
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on one or more TNFα-dependent transcriptional repressor(s).
The difference in responders versus non-responders could
then result from genetic polymorphisms in binding sites for
such repressors.
This situation of variations in binding of transcription factors
has been previously described in RA [11,44]. Notably, the -
308G/G genotype of the TNFα gene promoter is known to be
associated with a better response to infliximab compared to
the -308A/G or A/A genotype [11]. Other binding sites for
repressor(s) could be located in any gene that belongs to the
pathway from TNFα signalling to its indirect target genes
whose transcripts were found here. If so, identifying such bind-
ing site polymorphisms that could predict the extent of respon-
siveness to TBA deserves further studies. Beyond this, it might
well be worth combining the HLA-DRB1 genotype, itself a
predictor of responsiveness to methotrexate/sulphasalazine/
hydroxychloroquine in RA [45], with our measure of informa-
tive transcript levels, as this might enhance the predictive
power of such indicators.
Conclusion
The combined levels of a small set of discriminative transcripts
have provided for the first time a tool for the prediction of inf-
liximab/methotrexate efficacy in patients with long standing
(11 to 12 years) and very active RA. It remains to be seen
whether our predictive approach can prove useful in patients
with recent and/or moderate RA activity or in non-responders
given a higher dose of infliximab (>3 mg/kg). Other future
studies should identify further gene profiles whose changes
correlate with a responsiveness to other TBAs or treatments,
such as interleukin-1 receptor antagonists [46]. Ultimately, we
anticipate that a small series of parallel tests for such drug-
specific combinations of transcripts, as quantified on a specif-
ically designed DNA chip, should allow one to select the most
appropriate treatment for every RA patient, with the resulting
and beneficial eradication of the non-responder or moderate
responder phenotypes.
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